Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SALARIUS PHARMACEUTICALS, INC.

(SLRX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/21/2021 09/22/2021 09/23/2021 09/24/2021 09/27/2021 Date
1.05(c) 1.05(c) 1.11(c) 1.15(c) 1.09(c) Last
647 359 624 043 1 826 931 1 309 491 827 187 Volume
0.00% 0.00% +5.71% +3.60% -5.22% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 3,60 M - -
Net income 2021 -10,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,25x
Yield 2021 -
Sales 2022 2,29 M - -
Net income 2022 -18,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,17x
Yield 2022 -
Capitalization 48,8 M 48,8 M -
Capi. / Sales 2021 13,6x
Capi. / Sales 2022 21,3x
Nbr of Employees 8
Free-Float 98,5%
More Financials
Company
Salarius Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing epigenetic-based cancer treatments. The Company is developing targeted therapies to treat pediatric and other cancers, including solid tumors. The Company is targeting the epigenetic causes of cancers and is developing treatments for patients. The CompanyÔÇÖs lead product candidate, Seclidemstat (SP-2577), is a small... 
More about the company
Ratings of Salarius Pharmaceuticals, Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about SALARIUS PHARMACEUTICALS, INC.
09/27SALARIUS PHARMACEUTICALS : to Present at the Virtual Benzinga Healthcare Small Cap Confere..
AQ
09/22SALARIUS PHARMACEUTICALS : Partners With Cancer Epigenetics Institute to Research Drug Can..
MT
09/22SALARIUS PHARMACEUTICALS : and Fox Chase Cancer Center Launch Research Partnership
AQ
09/22Salarius Pharmaceuticals, Inc. Announces A Research Partnership with the Cancer Epigene..
CI
09/20SALARIUS PHARMACEUTICALS : Added to FTSE Global Micro Cap Index
AQ
09/16SALARIUS PHARMACEUTICALS, INC. : Other Events (form 8-K)
AQ
09/15Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum
GL
09/08SALARIUS PHARMACEUTICALS : to Present at the Virtual H.C. Wainwright 23rd Annual Global In..
AQ
08/25SALARIUS PHARMACEUTICALS : HC Wainwright Starts Salarius Pharmaceuticals at Buy With $5 Pr..
MT
08/20SALARIUS PHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Continued Lis..
AQ
08/12SALARIUS PHARMACEUTICALS : to Present at the Virtual Diamond Equity Research Emerging Grow..
AQ
08/05SALARIUS PHARMACEUTICALS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
08/05SALARIUS : Q2 Earnings Snapshot
AQ
08/05SALARIUS PHARMACEUTICALS : Earnings Flash (SLRX) SALARIUS PHARMACEUTICALS Reports Q2 Loss ..
MT
08/05SALARIUS PHARMACEUTICALS : Reports Second Quarter 2021 Financial Results and Highlights Re..
AQ
More news
News in other languages on SALARIUS PHARMACEUTICALS, INC.

- No features available -

More news
Analyst Recommendations on SALARIUS PHARMACEUTICALS, INC.
More recommendations
Chart SALARIUS PHARMACEUTICALS, INC.
Duration : Period :
Salarius Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SALARIUS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 1,09 $
Average target price 4,63 $
Spread / Average Target 324%
EPS Revisions
Managers and Directors
David J. Arthur President, Chief Executive Officer & Director
Mark J. Rosenblum Chief Financial Officer & Executive Vice President
William K. McVicar Chairman
Bruce J. McCreedy Director & Chief Scientific Officer
Nadeem Q. Mirza Senior Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
SALARIUS PHARMACEUTICALS, INC.26.37%51
MODERNA, INC.291.35%173 624
LONZA GROUP AG30.56%59 611
IQVIA HOLDINGS INC.38.49%50 128
CELLTRION, INC.-25.49%31 745
SEAGEN INC.-7.21%29 353